Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Nuveen Asset Management LLC grew its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 183,949 shares of the company’s stock after purchasing an additional 13,048 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.27% of EyePoint Pharmaceuticals worth $1,370,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC boosted its stake in shares of EyePoint Pharmaceuticals by 410.4% during the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after purchasing an additional 197,033 shares during the period. Bank of America Corp DE boosted its stake in shares of EyePoint Pharmaceuticals by 28.8% during the fourth quarter. Bank of America Corp DE now owns 648,030 shares of the company’s stock valued at $4,828,000 after purchasing an additional 145,065 shares during the period. abrdn plc purchased a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter valued at approximately $1,719,000. Raymond James Financial Inc. purchased a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter valued at approximately $76,000. Finally, Rhumbline Advisers boosted its stake in shares of EyePoint Pharmaceuticals by 16.1% during the fourth quarter. Rhumbline Advisers now owns 89,560 shares of the company’s stock valued at $667,000 after purchasing an additional 12,443 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Up 9.4%

Shares of EyePoint Pharmaceuticals stock opened at $8.12 on Wednesday. The company has a market cap of $558.75 million, a PE ratio of -4.06 and a beta of 1.58. The business has a 50 day moving average of $5.94 and a 200 day moving average of $6.92. EyePoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting analysts’ consensus estimates of ($0.65). The company had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. On average, research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Wall Street Zen raised EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, May 29th. Chardan Capital dropped their price objective on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Mizuho dropped their price objective on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, May 16th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.38.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.